Compound · clinical trials

Etoposide clinical trials

Also listed in trial records as Etoposide Phosphate, Vepesid, Toposar, VP16, EPEG, Lastet, VP 16, VP 16-213, VP 16213, VP16213, ETOP

Source: ClinicalTrials.gov, U.S. National Library of Medicine — the 164 trials in our China, Canada, Australia, Israel, France, Germany, Spain, Italy, USA, Mexico, Netherlands, South Korea, Poland, Japan, Belgium, Czechia, Austria, Turkey, Switzerland, Sweden, Denmark, Norway, UK, Brazil, Taiwan, Portugal, Ireland, Egypt, Singapore and India registers that name Etoposide as an intervention. Synced 9 Nov 2026

164Current trials

92Recruiting now

103Lead sponsors

30Country registers

Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov registry records · Synced 9 Nov 2026 · Editorial standards

At a glance

Etoposide is named as an intervention in 164 current clinical trials in our China, Canada, Australia, Israel, France, Germany, Spain, Italy, USA, Mexico, Netherlands, South Korea, Poland, Japan, Belgium, Czechia, Austria, Turkey, Switzerland, Sweden, Denmark, Norway, UK, Brazil, Taiwan, Portugal, Ireland, Egypt, Singapore and India registers. 92 are recruiting patients now. The most common phase is Phase 2. The sponsor with the most trials is Children's Oncology Group (12). The most-studied condition is Extensive-stage Small-cell Lung Cancer. The EU clinical trials register (CTIS) separately lists 7 authorised or ongoing trials.

Where Etoposide is approved

All regulators →

Of the three regulators tracked here, the first to approve Etoposide was the US, on 10 Nov 1983. It is approved in 2 of the 3 regulators tracked here.

USUnited States (FDA)

10 Nov 1983

Vepesid

NDA018768 on Drugs@FDA

First original NDA/BLA approval

EUEuropean Union (EMA)

No centralised EU authorisation (it may be authorised nationally)

First centralised authorisation

CACanada (Health Canada)

15 Feb 1994

Etoposide

Notice of Compliance 5787

First new-drug NOC

From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.

What health systems spend on Etoposide

All medicines →

ENNHS England

Not dispensed in the community in England in the last 12 months under this name

Net ingredient cost, community prescriptions

USUS Medicaid

$1.2m

21,550 prescriptions in 2025 · Etoposide, Etopophos

-39% on 2024

Amount Medicaid reimbursed, before rebates

From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.

How Etoposide works

All drug targets →

DNA topoisomerase II alpha inhibitor Inhibitor
Target: TOP2A DNA topoisomerase II alpha
✓ In ChEMBL and the Guide to Pharmacology

Other medicines acting on TOP2A

Doxorubicin Daunorubicin Adriamycin Idarubicin Mitoxantrone Dexrazoxane Amrubicin Teniposide

Diseases it has been tested for in clinical trials, by furthest phase

Ewing sarcomaPhase 3
Hodgkins lymphomaPhase 3
Acute lymphoblastic leukemiaPhase 3
Embryonal carcinomaPhase 3
Germ cell tumorPhase 3
GerminomaPhase 3
Nasopharyngeal carcinomaPhase 3
NeuroblastomaPhase 3
Nongerminomatous germ cell tumorPhase 3
Small cell lung carcinomaPhase 3

32 diseases in all

Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL1200645, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 6815, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.

Patient leaflets for Etoposide

The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.

IE
Ireland: 5 products on the HPRA list
Each product record links to the HPRA, which publishes the leaflet and SmPC.
UK
United Kingdom: Search MHRA Products
Patient information leaflets and SmPCs for UK-licensed products.
US
United States: Search DailyMed
FDA-approved labels, including patient and medication guides.

Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.

Reference identifiers for Etoposide

ChEMBL: CHEMBL1200645
PubChem CID: 6918092
CAS number: 117091-64-2
FDA UNII: 528XYJ8L1N
Wikidata: Q27260984

Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.

Trials by status

Recruiting9256%
Not yet open117%
Active, closed6037%
By invitation11%

Trials by phase

Phase 26338%
Phase 35634%
Phase 1/21811%
Phase 2/395%
Phase 185%
Not applicable42%
Observational32%
Phase 421%
Early Phase 111%

Clinical trials of Etoposide

164 trials

Study	Phase	Status	Lead sponsor	Registers
TC or BEP in Treating Patients With Malignant Ovarian Germ Cell Tumors NCT02429687 · ClinicalTrials.gov ↗ · Ovarian Germ Cell Cancer, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Beihua Kong	China
TC or BEP in Treating Patients With Ovarian Malignant Sex Cord-Stromal Tumors NCT02429700 · ClinicalTrials.gov ↗ · Ovarian Sex Cord Stromal Tumor, Ovarian Neoplasms, Ovarian Cancer	Phase 3	Recruiting	Beihua Kong	China
Accelerated v's Standard BEP Chemotherapy for Patients With Intermediate and Poor-risk Metastatic Germ Cell Tumours NCT02582697 · ClinicalTrials.gov ↗ · Germ Cell Tumor	Phase 3	Recruiting	University of Sydney	Australia
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors NCT03067181 · ClinicalTrials.gov ↗ · Childhood Extracranial Germ Cell Tumor, Extragonadal Embryonal Carcinoma, Germ Cell Tumor	Phase 3	Recruiting	Children's Oncology Group	India, Canada, Mexico, Japan, Australia, Israel
Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) NCT03126916 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Israel
Mitotane With or Without Cisplatin and Etoposide After Surgery in Treating Patients With Stage I-III Adrenocortical Cancer With High Risk of Recurrence NCT03583710 · ENSAT Stage I Adrenal Cortex Carcinoma, ENSAT Stage II Adrenal Cortex Carcinoma, ENSAT Stage III Adrenal Cortex Carcinoma	Phase 3	Recruiting	M.D. Anderson Cancer Center	Germany, France, Sweden, Poland
Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017 NCT03643276 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Pediatric	Phase 3	Recruiting	Martin Schrappe	Germany, Italy, Switzerland, Austria, Czechia, Australia, Israel
Clinical Trial for Patients With a Stage IV Childhood Renal Tumor, Comparing Upfront Vincristine, Actinomycin-D and Doxorubicin (Standard Arm) With Upfront Vincristine, Carboplatin and Etoposide (Experimental Arm) NCT03669783 · ClinicalTrials.gov ↗ · Childhood Renal Tumor	Phase 3	Recruiting	Assistance Publique Hopitaux De Marseille	France
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN) NCT04221035 · ClinicalTrials.gov ↗ · High-Risk Neuroblastoma, Patient With Insufficient Response Chemoimmunotherapy	Phase 3	Recruiting	Gustave Roussy, Cancer Campus, Grand Paris	Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway, Australia, Israel
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations NCT04293562 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia	Phase 3	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
First Line Chemotherapy for Classical Hodgkin Lymphoma in Russia (HL-Russia-1) NCT04638790 · Hodgkin Lymphoma, Adult	Phase 3	Recruiting	State Budgetary Healthcare Institution, National Medical Surgical Center N.A. N.I. Pirogov, Ministry of Health of Russia	India
Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer NCT05624996 · ClinicalTrials.gov ↗ · Locally Advanced Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8	Phase 3	Recruiting	NRG Oncology	Canada, Mexico
A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab NCT05675410 · ClinicalTrials.gov ↗ · Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Israel, Egypt
Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma NCT06172296 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Nodular, Neuroblastoma	Phase 3	Recruiting	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
A Study Using Risk Factors to Determine Treatment for Children With Favorable Histology Wilms Tumors (FHWT) NCT06401330 · Stage I Mixed Cell Type Kidney Wilms Tumor, Stage II Mixed Cell Type Kidney Wilms Tumor, Stage III Mixed Cell Type Kidney Wilms Tumor	Phase 3	Recruiting	Children's Oncology Group	Canada, Australia, Israel
Comparison Study of EAP and Disease-Specific Chemotherapy Regimens in Hematopoietic Stem Cell Mobilization for Lymphoma NCT06520163 · ClinicalTrials.gov ↗ · Non-Hodgkin's Lymphoma, Hematopoietic Stem Cell Mobilization	Phase 3	Recruiting	The Affiliated People's Hospital of Ningbo University	China
Comparison Study of EAP and CG Regimens for Mobilizing Hematopoietic Stem Cells in Multiple Myeloma Patients NCT06520176 · ClinicalTrials.gov ↗ · Multiple Myeloma, Hematopoietic Stem Cell Mobilization	Phase 3	Recruiting	The Affiliated People's Hospital of Ningbo University	China
A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combination) in Combination With Carboplatin Plus Etoposide to That of Atezolizumab With Carboplatin Plus Etoposide as First-Line Therapy in Participants With Extensive-Stage Small Cell Lung Cancer (TIGOS). NCT06646276 · Extensive-Stage Small Cell Lung Cancer	Phase 3	Recruiting	Bristol-Myers Squibb	UK, USA, India, China, Germany, France, Spain, Italy, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Australia
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer NCT06712355 · Extensive-stage Small-cell Lung Cancer	Phase 3	Recruiting	BioNTech SE	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Turkey, Japan, South Korea, Australia, Israel
Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma NCT06792253 · ClinicalTrials.gov ↗ · Relapsed/Refractory Diffuse Large B-Cell Lymphoma	Phase 3	Recruiting	BeBetter Med Inc	China
Omitting CTV for Primary Tumor in LS-SCLC NCT07008716 · ClinicalTrials.gov ↗ · SCLC, Limited Stage, Radiation Exposure, Radiotherapy Side Effect	Phase 3	Recruiting	Sun Yat-sen University	China
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy NCT07472517 · Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 3	Recruiting	Boehringer Ingelheim	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Poland, Switzerland, Austria, Czechia, Norway, Portugal, Turkey, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Singapore, Australia
A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing Chemotherapy Combined With Tislelizumab as First-line Treatment in Patients With Extensive-stage Small Cell Lung Cancer(PANKU-Lung07) NCT07502300 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 3	Recruiting	Sichuan Baili Pharmaceutical Co., Ltd	China
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer (epNEC) to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy NCT07544654 · Extrapulmonary Neuroendocrine Cancer (epNEC)	Phase 3	Recruiting	Boehringer Ingelheim	UK, USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Austria, Czechia, Norway, Portugal, Canada, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel
BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer (BrenDeLL-Lung01) NCT07625644 · Small Cell Lung Cancer Extensive Stage, Small-cell Lung Cancer, Small Cell Carcinoma	Phase 3	Recruiting	SystImmune Inc	USA, Germany, France, Spain, Italy, Poland, Czechia, Canada, Australia
A Study of YL201 in Combination With Serplulimab in Participants With Treatment-naïve Extensive-stage Small Cell Lung Cancer NCT07739758 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 3	Recruiting	MediLink Therapeutics (Suzhou) Co., Ltd	China
A Study Comparing QLC5508 in Combination With QL2107 Versus Tislelizumab Plus Platinum-based Chemotherapy in Participants Wih Treatment-naïve Extensive-Stage Small Cell Lung Cancer NCT07802821 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer	Phase 3	Recruiting	Qilu Pharmaceutical Co., Ltd	China
Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia NCT01949129 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukaemia	Phase 2/3	Recruiting	St. Anna Kinderkrebsforschung	Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Poland, Switzerland, Austria, Czechia, Norway, Turkey, Canada, Mexico, Australia, Israel
An International Clinical Program for the Diagnosis and Treatment of Children With Ependymoma NCT02265770 · Childhood Ependymoma	Phase 2/3	Recruiting	Centre Leon Berard	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Switzerland, Austria, Czechia, Norway
Ocular Conservative Treatment for Retinoblastoma : Efficacy of the New Management Strategies and Visual Outcome NCT04681417 · ClinicalTrials.gov ↗ · Retinoblastoma	Phase 2/3	Recruiting	Institut Curie	France
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma NCT05991388 · ClinicalTrials.gov ↗ · B-cell Non Hodgkin Lymphoma	Phase 2/3	Recruiting	University of Birmingham	Netherlands, Belgium, Sweden, Austria, Australia
Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment NCT06563245 · ClinicalTrials.gov ↗ · Classical Hodgkin Lymphoma, Child, Adolescent	Phase 2/3	Recruiting	Children's Cancer Group, China	China
Antiangiogenic Therapy for Children With Recurrent Medulloblastoma, Ependymoma, ATRT and Rare CNS Tumors NCT01356290 · ClinicalTrials.gov ↗ · Medulloblastoma Recurrent, Ependymoma Recurrent, ATRT Recurrent	Phase 2	Recruiting	Medical University of Vienna	France, Spain, Sweden, Denmark, Austria, Czechia, Norway
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT NCT04322318 · ClinicalTrials.gov ↗ · Anaplastic Kidney Wilms Tumor, Recurrent Kidney Wilms Tumor, Stage II Kidney Wilms Tumor	Phase 2	Recruiting	Children's Oncology Group	Canada, Mexico, Australia, Israel
PD-L1 Antibody (TQB2450) Plus Chemotherapy for Previously Untreated Limited- Stage Small-cell Lung Cancer NCT04539977 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
A Study of a New Way to Treat Children and Young Adults With a Brain Tumor Called NGGCT NCT04684368 · ClinicalTrials.gov ↗ · Central Nervous System Nongerminomatous Germ Cell Tumor, Choriocarcinoma, Embryonal Carcinoma	Phase 2	Recruiting	Children's Oncology Group	Canada, Australia, Israel
Tamoxifen Versus Etoposide After First Recurrence in GBM Patients NCT04765098 · ClinicalTrials.gov ↗ · Glioblastoma Multiforme	Phase 2	Recruiting	AHS Cancer Control Alberta	Canada
Mecapegfilgrastim With Chemotherapy for Peripheral Blood Stem Cell Mobilization in MM and Lymphoma NCT05294055 · ClinicalTrials.gov ↗ · Multiple Myeloma, Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
A Study to Give Treatment Inside the Eye to Treat Retinoblastoma NCT05504291 · ClinicalTrials.gov ↗ · Bilateral Retinoblastoma, Childhood Intraocular Retinoblastoma, Group D Retinoblastoma	Phase 2	Recruiting	Children's Oncology Group	Canada, Australia
Neoadjuvant Adebrelimab Plus Etoposide and Cisplatin in Neuroendocrine Bladder Carcinoma NCT06091124 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinoma of the Bladder, Bladder Cancer	Phase 2	Recruiting	RenJi Hospital	China
Adebelizumab Combined With Chemotherapy and Radiotherapy Treat ES-SCLC NCT06125041 · ClinicalTrials.gov ↗ · Extensive Small Cell Lung Cancer	Phase 2	Recruiting	Qianfoshan Hospital	China
Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma NCT06140966 · ClinicalTrials.gov ↗ · Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma	Phase 2	Recruiting	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	China
Clinical Study of Induction Therapy Options Based on Molecular Subtyping and MRD in Children and Adolescents With AML NCT06221683 · ClinicalTrials.gov ↗ · AML, Childhood, Acute Myeloid Leukemia	Phase 2	Recruiting	Children's Hospital of Soochow University	China
Efficacy and Safety of Induction Chemotherapy for Olfactory Neuroblastoma (ESICON) NCT06255210 · ClinicalTrials.gov ↗ · Olfactory Neuroblastoma	Phase 2	Recruiting	Hongmeng Yu	China
Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial NCT06256237 · ClinicalTrials.gov ↗ · Limited Stage Small Cell Lung Cancer	Phase 2	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
CHIP-AML22/Quizartinib: Quizartinib + Chemotherapy in Newly Diagnosed Pediatric FLT3-ITD+ and NPM1wt AML Patients NCT06262438 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia in Children	Phase 2	Recruiting	Princess Maxima Center for Pediatric Oncology	Netherlands
Serplulimab Combined With CCRT for LS-SCLC. NCT06295926 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	Peking Union Medical College Hospital	China
A Study of Lower Radiotherapy Dose to Treat Children With CNS Germinoma NCT06368817 · ClinicalTrials.gov ↗ · Basal Ganglia Germinoma, Diabetes Insipidus, Germinoma	Phase 2	Recruiting	Children's Oncology Group	Canada, Australia, Israel
Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain Metastasis NCT06418594 · ClinicalTrials.gov ↗ · HER2-negative Breast Cancer Brain Metastases	Phase 2	Recruiting	Beijing 302 Hospital	China
AGNOSTIC THERAPY IN A PHASE II SINGLE-ARM STUDY IN FIRST-LINE TREATMENT OF DURVALUMAB IN ASSOCIATION WITH CARBOPLATIN OR CISPLATIN AND ETOPOSIDE IN PATIENTS AFFECTED BY EXTENSIVE STAGE - EXTRAPULMONARY SMALL CELL CARCINOMA NCT06464068 · ClinicalTrials.gov ↗ · Extrapulmonary Small Cell Carcinoma	Phase 2	Recruiting	Gruppo Oncologico Italiano di Ricerca Clinica	Italy
A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung Cancer NCT06483282 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Limited Stage	Phase 2	Recruiting	Jin Ying	China
Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial NCT06485544 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC)	Phase 2	Recruiting	Tang-Du Hospital	China
Linperlisib Combined With Immunochemotherapy in Relapsed/Refractory LBCL NCT06489808 · ClinicalTrials.gov ↗ · Relapsed/Refractory Large B-Cell Lymphoma	Phase 2	Recruiting	Institute of Hematology & Blood Diseases Hospital, China	China
Maintenance Lurbinectedin in Combination With Serplulimab for Patients With ES-SCLC NCT06497530 · ClinicalTrials.gov ↗ · Extensive-Stage Small Cell Lung Cancer	Phase 2	Recruiting	Guangzhou Institute of Respiratory Disease	China
Entrectinib as a Single Agent in Upfront Therapy for Children <3 Years of Age With NTRK1/2/3 or ROS1-FUSED CNS Tumors NCT06528691 · ClinicalTrials.gov ↗ · High Grade Glioma, CNS Tumor	Phase 2	Recruiting	St. Jude Children's Research Hospital	Brazil
Tislelizumab Combined With Chemotherapy and Thoracic Radiotherapy in ES-SCLC NCT06536868 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Recruiting	Second Hospital of Shanxi Medical University	China
Atezolizumab and Rechallenge Chemotherapy in Relapsed Patients With Extensive-stage Small Cell Lung Cancer (ES-SCLC). NCT06663098 · ClinicalTrials.gov ↗ · Extensive Stage Small Cell Lung Cancer (ES-SCLC)	Phase 2	Recruiting	Gruppo Oncologico Italiano di Ricerca Clinica	Italy
First Line Therapy for Extensive SCLC Patients, Treated with Chemo+Keytruda Followed by Keytuda+Trodelvy NCT06667167 · ClinicalTrials.gov ↗ · NSCLC (non-small Cell Lung Cancer)	Phase 2	Recruiting	Nir Peled	Israel
Irinotecan Liposome (II) or Etoposide Combined With Adebrelimab and Carboplatin in the Treatment of ES-SCLC NCT06739928 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Recruiting	Guangzhou Institute of Respiratory Disease	China
Phase II Study of Ivonescimab and Cadonilimab in Combination with Chemotherapy in Patients with ES-SCLC NCT06769971 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	Sichuan University	China
Using Tumor Models to Determine Treatments NCT06813079 · ClinicalTrials.gov ↗ · Pancreatic Ductal Carcinoma, Advanced Cancer, Epithelial Tumor	Phase 2	Recruiting	University Health Network, Toronto	Canada
Sintilimab Combined With Tafolecimab and Chemotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer NCT07061535 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer (ES-SCLC), Extensive Stage Lung Small Cell Cancer, Extensive-Stage Small-Cell Lung Cancer	Phase 2	Recruiting	Second Affiliated Hospital, Zhejiang University, School of Medicine	China
Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy NCT07141264 · ClinicalTrials.gov ↗ · SCLC,Extensive Stage	Phase 2	Recruiting	Tang-Du Hospital	China
A Study to Evaluate the Optimal Dose, Adverse Events and Change in Disease Activity of Intravenous ABBV-706 in Combination With Atezolizumab Versus Standard of Care as First-Line Treatment in Adult Participants With Previously Untreated Extensive Stage Small Cell Lung Cancer NCT07155174 · Small Cell Lung Cancer	Phase 2	Recruiting	AbbVie	USA, China, Germany, Spain, Italy, Belgium, Poland, Turkey, Japan, South Korea, Taiwan, Israel
A Study of Ivonescimab in First-Line ES-SCLC NCT07245446 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer (ES-SCLC)	Phase 2	Recruiting	Akeso	China
A Trial of SHR-7787 Injection Combined With Other Anti-tumor Drugs in Patients With Malignant Solid Tumors NCT07268040 · ClinicalTrials.gov ↗ · Malignant Solid Tumors	Phase 2	Recruiting	Shanghai Hengrui Pharmaceutical Co., Ltd	China
SKB500 Combinations in Patients With Small Cell Lung Cancer NCT07296809 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Phase 2	Recruiting	Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd	China
Dostarlimab, Cisplatin and Etoposide in Combination With Radiotherapy in Sandwich Sequence for Small Cell Neuroendocrine Cervical Carcinoma NCT07336147 · ClinicalTrials.gov ↗ · Female	Phase 2	Recruiting	Chang Gung Memorial Hospital	Taiwan
Teniposide, Cisplatin and Serplulimab for Treatment of ES-SCLC, a Randomized Controlled Study NCT07583511 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Phase 2	Recruiting	Sun Yat-sen University	China
Low-dose Thoracic Radiotherapy Followed by Adebrelimab Plus Chemotherapy, and Then Sequential Maintenance Therapy With Adebrelimab for Extensive-stage Small Cell Lung Cancer NCT07583550 · ClinicalTrials.gov ↗ · Lung, Radiotherapy	Phase 2	Recruiting	Jiangmen Central Hospital	China
Lenalidomide in Combination With R-DA-EPOCH in Patients With Untreated DLBCL With MYC Rearrangement NCT04432714 · ClinicalTrials.gov ↗ · DLBCL, Untreated, MYC Gene Rearrangement	Phase 1/2	Recruiting	The First Affiliated Hospital with Nanjing Medical University	China
Metronomic Chemotherapy in Wilms Tumor (MetroWilms-1906) NCT05384821 · ClinicalTrials.gov ↗ · Wilms Tumor	Phase 1/2	Recruiting	Centre Oscar Lambret	France
A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma NCT05533775 · Mature B-Cell Non-Hodgkin Lymphoma	Phase 1/2	Recruiting	Hoffmann-La Roche	USA, China, Germany, France, Spain, Italy, Denmark, Poland, Czechia, Brazil, South Korea, Australia
A Study of Peluntamig (PT217) in Patients With Neuroendocrine Carcinomas Expressing DLL3 (the SKYBRIDGE Study) NCT05652686 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer (SCLC), Large Cell Neuroendocrine Cancer (LCNEC), Neuroendocrine Prostate Cancer (NEPC)	Phase 1/2	Recruiting	Phanes Therapeutics	USA
IN10018 Combination Therapy in Treatment-naïve ES-SCLC NCT06030258 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	InxMed (Shanghai) Co., Ltd	China
A Clinical Trial of LBL-024 Combined With Etoposide and Platinum in Patients With Advanced Neuroendocrine Carcinoma NCT06157827 · ClinicalTrials.gov ↗ · Advanced Neuroendocrine Carcinoma	Phase 1/2	Recruiting	Nanjing Leads Biolabs Co.,Ltd	China
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC NCT06217757 · ClinicalTrials.gov ↗ · Lung Cancer, Extensive-stage Small-cell Lung Cancer	Phase 1/2	Recruiting	Sichuan University	China
Selinexor With ICE Chemotherapy in Secondary Central Nervous System Involving B-cell Non-Hodgkin Lymphoma NCT06552559 · ClinicalTrials.gov ↗ · B-cell Lymphoma Recurrent, B-cell Lymphoma Refractory, CNS Metastases	Phase 1/2	Recruiting	Samsung Medical Center	South Korea
A Phase I/II Study of CS2009 in Participants With Advanced Solid Tumors NCT06741644 · Advanced Solid Tumors	Phase 1/2	Recruiting	CStone Pharmaceuticals	USA, China, Australia
Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC NCT07136285 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 1/2	Recruiting	Newsoara HYK Biopharmaceutical (Shanghai) Co., Ltd	China
A Clinical Study of Gocatamig (MK-6070) and Infinatamab Deruxtecan (MK-2400) in People With Small Cell Lung Cancer (MK-6070-003) NCT07227597 · Small Cell Lung Cancer Extensive Stage	Phase 1/2	Recruiting	Merck Sharp & Dohme LLC	USA, China, Germany, Spain, Italy, Poland, Turkey, South Korea, Israel
Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) NCT07525466 · ClinicalTrials.gov ↗ · Extranodal NK T Cell Lymphoma, Hemophagocytic Lymphohistiocytosis (HLH)	Phase 1/2	Recruiting	Beijing Tongren Hospital	China
A Study to Test Obrixtamig in Combination With Pumitamig in People With Advanced Small Cell Lung Cancer (Dareon®-Rosetta35) NCT07843940 · Extensive-stage Small Cell Lung Carcinoma, Advanced Small Cell Lung Cancer	Phase 1/2	Recruiting	Boehringer Ingelheim	USA, China, Germany, France, Spain, Netherlands, Belgium, Poland, Japan, Australia
A Phase Ib Clinical Study on the Safety and Efficacy of HC010 Combined With Chemotherapy in Lung Cancer NCT07381829 · ClinicalTrials.gov ↗ · Advanced Solid Tumor Cancer	Phase 1	Recruiting	HC Biopharma Inc	China
Prospective Cohort for Adult Hemophagocytosis NCT03117010 · ClinicalTrials.gov ↗ · Hemophagocytic Lymphohistiocytoses	Observational	Recruiting	Samsung Medical Center	South Korea
A Study on the Efficacy of Atezolizumab Combined with Chemotherapy NCT06780826 · ClinicalTrials.gov ↗ · Lung Cancer, Small Cell	Observational	Recruiting	Shanghai Pulmonary Hospital, Shanghai, China	China
Prediction of Response to PD-L1 Inhibitor After Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer Using Multi-omics-based Liquid Biopsy NCT06869239 · ClinicalTrials.gov ↗ · Limited-stage Small Cell Lung Cancer (LS-SCLC)	Observational	Recruiting	Peking University Cancer Hospital & Institute	China
Treatment for Classical Hodgkin Lymphoma in Children and Adolescents NCT02797717 · ClinicalTrials.gov ↗ · Classical Hodgkins Lymphoma in Children and Adolescents.	Not applicable	Recruiting	GALIA AVRAHAMI	Israel
A Randomized Controlled Study of High-dose Cyclophosphamide Induction Therapy in Adult Patients With HLH NCT05936086 · ClinicalTrials.gov ↗ · Hemophagocytic Syndrome	Not applicable	Recruiting	shifeng Lou	China
Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung Cancer NCT06480864 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer	Not applicable	Recruiting	Yunpeng Liu	China
Primary RPLND Versus Systemic Chemotherapy in Good-prognosis Metastatic Testicular Cancer NCT07498959 · ClinicalTrials.gov ↗ · Testicular Cancer, Seminoma, Quality of Life	Not applicable	Recruiting	Sahlgrenska University Hospital	Sweden
Pilot Study of IT Topotecan and Maintenance Chemotherapy for HR-EBTs in Children < 6 Years, Post Consolidation NCT06942039 · ClinicalTrials.gov ↗ · CNS Embryonal Tumor, CNS, Medulloblastoma, Atypical Teratoid Rhabdoid Tumor	Early Phase 1	Recruiting	C17 Council	Canada
Benmelstobart, Anlotinib and Chemotherapy as First-line Treatment for Extensive-stage Small-cell Lung Cancer NCT06931145 · ClinicalTrials.gov ↗ · Extensive-stage Small Cell Lung Cancer	Phase 4	Not yet open	Peking Union Medical College Hospital	China
Comparison of Two Etoposide Initiation Strategies for Severe Hemophagocytic Lymphohistiocytosis NCT07497438 · ClinicalTrials.gov ↗ · Hemophagocytic Lymphohistiocytosis	Phase 3	Not yet open	Assistance Publique - Hôpitaux de Paris	France
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC NCT07720193 · ClinicalTrials.gov ↗ · Advanced Extrapulmonary Neuroendocrine Carcinoma	Phase 3	Not yet open	Nanjing Leads Biolabs Co.,Ltd	China
ZG005 Plus Etoposide and Cisplatin vs. Etoposide and Cisplatin as First-Line Treatment for Advanced Neuroendocrine Carcinoma NCT07833839 · ClinicalTrials.gov ↗ · Neuroendocrine Carcinomas (NEC)	Phase 3	Not yet open	Suzhou Zelgen Biopharmaceuticals Co.,Ltd	China
A Single-arm, Multicenter, Prospective Phase II Clinical Study of Apatinib in Combination With Adebrelimab and EC Regimen in the First-line Treatment of Extensive Small Cell Lung Cancer NCT06786312 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Not yet open	Fujian Cancer Hospital	China
Toripalimab Combined With Chemotherapy as Adjuvant Therapy for Incidental Small Cell Lung Cancer After Radical Resection of Lung Cancer: A Single-Center, Randomized Controlled Clinical Study Protocol Number: LungMate-033 NCT07097948 · ClinicalTrials.gov ↗ · Postoperative Incidental Small Cell Lung Cancer, Toripalimab Adjuvant Therapy Evaluation	Phase 2	Not yet open	Shanghai Pulmonary Hospital, Shanghai, China	China
Etoposide Capsules Combined With Bevacizumab and Iparomlimab and Tuvonralimab in the Treatment of Platinum Resistant or Platinum Refractory Ovarian Cancer NCT07117877 · ClinicalTrials.gov ↗ · Platinum Resistant Ovarian Cancer, Platinum Refractory Epithelial Ovarian Cancer, Ovarian Cancer (OvCa)	Phase 2	Not yet open	Fudan University	China
Open-Label, Biomarker-Integrated Umbrella Trial for First-Line Treatment of Extensive-stage Small Cell Lung Cancer NCT07172412 · ClinicalTrials.gov ↗ · Extensive Stage Lung Small Cell Cancer	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
A Phase II Study of Benmelstobart + Anlotinib + Chemotherapy as First-Line Treatment for LCNEC and EP-NEC NCT07510594 · ClinicalTrials.gov ↗ · Large-Cell Neuroendocrine Carcinoma of the Lung, Extrapulmonary Neuroendocrine Carcinoma	Phase 2	Not yet open	Tianjin Medical University Cancer Institute and Hospital	China
GELAD-Based Response-Adapted Treatment for Early-Stage Extranodal NK/T-Cell Lymphoma NCT07768943 · ClinicalTrials.gov ↗ · Natural Killer/T-cell Lymphoma	Phase 2	Not yet open	Fudan University	China
A Study of Sulfatinib on Relapsed or Refractory Drug Resistant Osteosarcoma NCT05590572 · ClinicalTrials.gov ↗ · Osteosarcoma	Phase 1/2	Not yet open	Second Affiliated Hospital, Zhejiang University, School of Medicine	China, South Korea
Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia NCT07920796 · ClinicalTrials.gov ↗ · Acute Leukemia, High Risk, Acute Leukemia Refractory, Acute Leukemia, Relapsed	Phase 2	By invitation	Guangdong Second Provincial General Hospital	China
HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors NCT02875314 · ClinicalTrials.gov ↗ · Medulloblastoma, Central Nervous System Embryonal Tumors	Phase 4	Active, closed	Parth Patel	Canada
Combined Chemotherapy With or Without Zoledronic Acid for Patients With Osteosarcoma NCT00470223 · ClinicalTrials.gov ↗ · Sarcoma	Phase 3	Active, closed	UNICANCER	France
Combination Chemotherapy With or Without Blinatumomab in Treating Patients With Newly Diagnosed BCR-ABL-Negative B Lineage Acute Lymphoblastic Leukemia NCT02003222 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia NCT02101853 · ClinicalTrials.gov ↗ · Recurrent B Acute Lymphoblastic Leukemia	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia, Israel
Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma NCT02112916 · ClinicalTrials.gov ↗ · Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Australia, Israel
Brentuximab Vedotin and Combination Chemotherapy in Treating Children and Young Adults With Stage IIB, Stage IIIB, IVA, or IVB Hodgkin Lymphoma NCT02166463 · ClinicalTrials.gov ↗ · Ann Arbor Stage IIB Hodgkin Lymphoma, Ann Arbor Stage IIIB Hodgkin Lymphoma, Ann Arbor Stage IVA Hodgkin Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Mexico, Israel
Response and Biology-Based Risk Factor-Guided Therapy in Treating Younger Patients With Non-high Risk Neuroblastoma NCT02176967 · ClinicalTrials.gov ↗ · Ganglioneuroblastoma, Localized Resectable Neuroblastoma, Localized Unresectable Neuroblastoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma NCT02306161 · ClinicalTrials.gov ↗ · Metastatic Ewing Sarcoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Bone Marrow	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Israel
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients With Relapsed or Refractory Germ Cell Tumors NCT02375204 · Germ Cell Tumor, Teratoma, Choriocarcinoma	Phase 3	Active, closed	Alliance for Clinical Trials in Oncology	Ireland, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Switzerland, Australia
Response-Based Chemotherapy in Treating Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome in Younger Patients With Down Syndrome NCT02521493 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Down Syndrome, Myelodysplastic Syndrome	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia
Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia NCT03007147 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, B Acute Lymphoblastic Leukemia, Mixed Phenotype Acute Leukemia	Phase 3	Active, closed	Children's Oncology Group	Germany, France, Italy, Netherlands, Belgium, Sweden, Switzerland, Austria, Czechia, Canada, Mexico, Australia, Israel
Paediatric Hepatic International Tumour Trial NCT03017326 · Hepatoblastoma, Carcinoma, Hepatocellular	Phase 3	Active, closed	University of Birmingham	Ireland, Germany, France, Spain, Netherlands, Belgium, Poland, Switzerland, Austria, Czechia, Norway, Israel
Treatment of Newly Diagnosed Acute Lymphoblastic Leukemia in Children and Adolescents NCT03020030 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Pediatric	Phase 3	Active, closed	Dana-Farber Cancer Institute	Canada
Durvalumab ± Tremelimumab in Combination With Platinum Based Chemotherapy in Untreated Extensive-Stage Small Cell Lung Cancer (CASPIAN) NCT03043872 · Small Cell Lung Carcinoma Extensive Disease	Phase 3	Active, closed	AstraZeneca	USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Czechia, Turkey, Brazil, Japan, South Korea, Taiwan, Israel
Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents NCT03206671 · Mature B-cell Non-Hodgkin Lymphoma	Phase 3	Active, closed	University Hospital Muenster	Germany, Sweden, Denmark, Switzerland, Austria, Czechia, Norway
Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery NCT03533582 · ClinicalTrials.gov ↗ · Childhood Hepatocellular Carcinoma, Childhood Malignant Liver Neoplasm, Fibrolamellar Carcinoma	Phase 3	Active, closed	Children's Oncology Group	Canada, Mexico, Australia, Israel
Testing the Addition of a New Immunotherapy Drug, Atezolizumab (MPDL3280A), to the Usual Chemoradiation (CRT) Therapy Treatment for Limited Stage Small Cell Lung Cancer (LS-SCLC) NCT03811002 · ClinicalTrials.gov ↗ · Limited Stage Lung Small Cell Carcinoma, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Norway, Mexico, Japan, Egypt
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer NCT04092283 · ClinicalTrials.gov ↗ · Recurrent Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8	Phase 3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
Study of Pembrolizumab With Concurrent Chemoradiation Therapy Followed by Pembrolizumab With or Without Olaparib in Stage III Non-Small Cell Lung Cancer (NSCLC) (MK-7339-012/KEYLYNK-012) NCT04380636 · Lung Neoplasms, Carcinoma, Non-Small-Cell Lung	Phase 3	Active, closed	Merck Sharp & Dohme LLC	UK, USA, China, Germany, France, Spain, Italy, Poland, Czechia, Norway, Turkey, Canada, Mexico, Japan, South Korea
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma NCT04759586 · ClinicalTrials.gov ↗ · Primary Mediastinal Large B-Cell Lymphoma	Phase 3	Active, closed	National Cancer Institute (NCI)	Canada, Australia
A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer NCT05091567 · Small-Cell Lung Cancer	Phase 3	Active, closed	Hoffmann-La Roche	UK, USA, Germany, Spain, Italy, Belgium, Poland, Turkey, Mexico, South Korea, Taiwan
Pembrolizumab/Vibostolimab (MK-7684A) or Atezolizumab in Combination With Chemotherapy in First Line Treatment of Extensive-Stage Small Cell Lung Cancer (MK-7684A-008/KEYVIBE-008) NCT05224141 · Small Cell Lung Carcinoma	Phase 3	Active, closed	Merck Sharp & Dohme LLC	Ireland, UK, USA, China, Germany, France, Spain, Italy, Netherlands, Poland, Austria, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma NCT05605899 · High-risk Large B-cell Lymphoma (LBCL)	Phase 3	Active, closed	Kite, A Gilead Company	UK, USA, Germany, France, Spain, Italy, Netherlands, Austria, Portugal, Canada, Japan, Australia
A Trial to Learn How Effective and Safe Odronextamab is Compared to Standard of Care for Adult Participants With Previously Treated Aggressive B-cell Non-Hodgkin Lymphoma NCT06230224 · ClinicalTrials.gov ↗ · B-Cell Non-Hodgkin Lymphoma (B-NHL)	Phase 3	Active, closed	Regeneron Pharmaceuticals	Spain, Turkey, Brazil, South Korea, Taiwan, Singapore, Australia
A Phase III, Randomised Study of Adjuvant Dato-DXd in Combination With Rilvegostomig or Rilvegostomig Monotherapy Versus Standard of Care, Following Complete Tumour Resection, in Participants With Stage I Adenocarcinoma NSCLC Who Are ctDNA-positive or Have High-risk Pathological Features NCT06564844 · Non-small Cell Lung Cancer	Phase 3	Active, closed	AstraZeneca	USA, Turkey, Canada, Brazil, Japan, Taiwan
A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC) NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer	Phase 3	Active, closed	Amgen	USA, China, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Poland, Switzerland, Austria, Portugal, Turkey, Brazil, Mexico, Japan, South Korea, Taiwan, Australia, Israel, Egypt
A Phase III, Randomized, Double-blind, Multi-center Trial Comparing Efficacy and Safety of Trilaciclib Versus Placebo in Participants With Limited-stage Small Cell Lung Cancer NCT07881705 · ClinicalTrials.gov ↗ · Myelosuppression	Phase 3	Active, closed	Jiangsu Simcere Pharmaceutical Co., Ltd	China
Mature B-Cell Lymphoma And Leukemia Study III NCT01046825 · ClinicalTrials.gov ↗ · Mature B-Cell Lymphoma	Phase 2/3	Active, closed	St. Jude Children's Research Hospital	Singapore, Egypt
Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma NCT03117751 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma	Phase 2/3	Active, closed	St. Jude Children's Research Hospital	Australia
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas NCT03984448 · Diffuse Large B-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Double-Expressor Lymphoma	Phase 2/3	Active, closed	National Cancer Institute (NCI)	Mexico, Israel
A Study of PLB1001 Enteric Capsules in the Treatment of sGBM/IDH Mutant Glioblastoma Patients With the ZM Fusion Gene (FUGEN). NCT06105619 · ClinicalTrials.gov ↗ · Glioblastoma	Phase 2/3	Active, closed	Beijing Pearl Biotechnology Limited Liability Company	China
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma NCT02436707 · ClinicalTrials.gov ↗ · Lymphoma	Phase 2	Active, closed	Canadian Cancer Trials Group	Canada
Cisplatin and Etoposide Versus Temozolomide and Capecitabine in Patients With Advanced Poorly Differentiated (G3) Non-Small Cell Gastrointestinal Neuroendocrine Carcinomas NCT02595424 · ClinicalTrials.gov ↗ · Gastric Neuroendocrine Carcinoma, Intestinal Neuroendocrine Carcinoma, Pancreatic Neuroendocrine Carcinoma	Phase 2	Active, closed	ECOG-ACRIN Cancer Research Group	Mexico, Israel
Conservative Treatments of Retinoblastoma NCT02866136 · ClinicalTrials.gov ↗ · Retinoblastoma, Children, Retinal Neoplasm	Phase 2	Active, closed	Institut Curie	France
Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009) NCT02870907 · ClinicalTrials.gov ↗ · Retinoblastoma	Phase 2	Active, closed	Institut Curie	France
Brentuximab Vedotin and Combination Chemotherapy in Treating Patients With CD30-Positive Peripheral T-cell Lymphoma NCT03113500 · ClinicalTrials.gov ↗ · Adult T-Cell Leukemia/Lymphoma, Anaplastic Large Cell Lymphoma, ALK-Negative, Anaplastic Large Cell Lymphoma, ALK-Positive	Phase 2	Active, closed	City of Hope Medical Center	Canada
Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667) NCT03407144 · Hodgkin Lymphoma	Phase 2	Active, closed	Merck Sharp & Dohme LLC	UK, USA, Germany, France, Spain, Italy, Netherlands, Czechia, Brazil, Mexico, South Korea
Very Early PET-response Adapted Targeted Therapy for Advanced Hodgkin Lymphoma: a Single -Arm Phase II Study NCT03517137 · ClinicalTrials.gov ↗ · Advanced Hodgkin Lymphoma	Phase 2	Active, closed	European Organisation for Research and Treatment of Cancer - EORTC	Spain, Netherlands, Belgium, Denmark, Poland, Portugal
A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML NCT03591510 · ClinicalTrials.gov ↗ · FLT3-mutated Acute Myeloid Leukemia	Phase 2	Active, closed	Novartis Pharmaceuticals	Germany, Italy, Poland, Czechia, Turkey, Japan, South Korea
Reduced Intensity Radio-chemotherapy for Stage IIA/B Seminoma NCT03937843 · ClinicalTrials.gov ↗ · Seminoma, Testicular Cancer	Phase 2	Active, closed	Swiss Cancer Institute	Germany, Switzerland
Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD) NCT03944772 · Non-Small Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, Spain, Italy, Netherlands, Sweden, Denmark, Norway, Japan, South Korea
Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). NCT04472949 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer, Lung Cancer	Phase 2	Active, closed	Swiss Cancer Institute	Switzerland
Study of AZD2811 + Durvalumab in ES-SCLC NCT04745689 · ClinicalTrials.gov ↗ · Small-Cell Lung Cancer	Phase 2	Active, closed	AstraZeneca	USA, Spain, Poland, South Korea
Study of Pembrolizumab, Lenvatinib and Chemotherapy Combination in First Line Extensive-stage Small Cell Lung Cancer NCT05384015 · ClinicalTrials.gov ↗ · Small Cell Lung Cancer Extensive Stage	Phase 2	Active, closed	Fundación GECP	Spain
Chemo-immunotherapy in Patients With Resectable Merkel Cell Carcinoma Prior to Surgery NCT05594290 · ClinicalTrials.gov ↗ · Merkel Cell Carcinoma	Phase 2	Active, closed	Gruppo Oncologico del Nord-Ovest	Italy
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC NCT05765825 · ClinicalTrials.gov ↗ · Extensive-stage Small-cell Lung Cancer	Phase 2	Active, closed	Sichuan University	China
A Study of PM8002 (Anti-PD-L1/VEGF) in Combination With Chemotherapy in Patients With ES-SCLC NCT05844150 · ClinicalTrials.gov ↗ · SCLC	Phase 2	Active, closed	Biotheus Inc	China
Safety and Efficacy Evaluation of Serplulimab Plus Chemo in SCLC Transformed From EGFR-mutated NSCLC After Treatment NCT05957510 · ClinicalTrials.gov ↗ · Small-cell Lung Cancer	Phase 2	Active, closed	Guangdong Association of Clinical Trials	China
Safety, Preliminary Effectiveness of BNT327, an Investigational Therapy for Patients With Small-cell Lung Cancer in Combination With Chemotherapy NCT06449209 · Extensive-stage Small-cell Lung Cancer, Small-cell Lung Cancer	Phase 2	Active, closed	BioNTech SE	UK, USA, Turkey, South Korea, Australia
Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I NCT02553460 · ClinicalTrials.gov ↗ · Acute Lymphoblastic Leukemia	Phase 1/2	Active, closed	St. Jude Children's Research Hospital	Canada
Safety and Efficacy of Quizartinib in Children and Young Adults With Acute Myeloid Leukemia (AML), a Cancer of the Blood NCT03793478 · Acute Myeloid Leukemia	Phase 1/2	Active, closed	Daiichi Sankyo	USA, France, Spain, Italy, Netherlands, Belgium, Sweden, Denmark, Canada, Israel
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC NCT06477523 · ClinicalTrials.gov ↗ · SCLC, Extensive Stage	Phase 1/2	Active, closed	Sichuan University	China
Safety and Efficacy of HCB101 in Combination With Multiple Agents in Patients With Advanced Solid Tumors NCT06771622 · ClinicalTrials.gov ↗ · Solid Cancer	Phase 1/2	Active, closed	FBD Biologics Limited	China
Safety Study of AG-120 or AG-221 in Combination With Induction and Consolidation Therapy in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML) With an IDH1 and/or IDH2 Mutation NCT02632708 · ClinicalTrials.gov ↗ · Newly Diagnosed Acute Myeloid Leukemia (AML), Untreated AML, AML Arising From Myelodysplastic Syndrome (MDS)	Phase 1	Active, closed	Institut de Recherches Internationales Servier	Germany, Netherlands
Testing the Addition of an Anti-cancer Drug, M3814, to the Usual Treatment (Mitoxantrone, Etoposide, and Cytarabine) for Relapsed or Refractory Acute Myeloid Leukemia NCT03983824 · ClinicalTrials.gov ↗ · Recurrent Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia	Phase 1	Active, closed	National Cancer Institute (NCI)	Israel
First-Line Tarlatamab in Combination With Carboplatin, Etoposide, and PD-L1 Inhibitor in Subjects With Extensive Stage Small Cell Lung Cancer (ES-SCLC) NCT05361395 · Extensive Stage Small Cell Lung Cancer	Phase 1	Active, closed	Amgen	USA, Germany, France, Spain, Italy, Netherlands, Belgium, Denmark, Switzerland, Canada, Japan, South Korea, Taiwan, Australia, Israel
Study of RYZ101 in Combination With SoC in Subjects With SSTR+ ES-SCLC NCT05595460 · SCLC,Extensive Stage	Phase 1	Active, closed	RayzeBio, Inc	USA
DAREONᵀᴹ-8: A Study to Test How Well Different Doses of BI 764532 in Addition to Standard of Care Are Tolerated by People With Advanced Small Cell Lung Cancer NCT06077500 · Small Cell Lung Carcinoma (SCLC)	Phase 1	Active, closed	Boehringer Ingelheim	USA, Germany, France, Spain, Belgium, Poland, Switzerland, Japan
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers NCT06132113 · Neuroendocrine Neoplasms	Phase 1	Active, closed	Boehringer Ingelheim	USA, Germany, France, Spain, Netherlands, Belgium, Sweden, Japan
A Clinical Study of SHR-1316 (SC) Combined With Carboplatin and Etoposide as First-line Treatment for Extensive Stage Small Cell Lung Cancer NCT07009457 · ClinicalTrials.gov ↗ · Widespread Small Cell Lung Cancer	Phase 1	Active, closed	Suzhou Suncadia Biopharmaceuticals Co., Ltd	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.

Etoposide in the EU trials register (CTIS)

7 trials

Authorised or ongoing trials in the EU Clinical Trials Information System that list a product containing Etoposide. Many trials are registered in both CTIS and ClinicalTrials.gov, so these are shown separately rather than added to the count above. Trials with a site in Ireland are listed first.

Study	Phase	Status	Sponsor	Countries
"EURbG2": A European prospective study of patients with unilateral retinoblastoma requiring enucleation, either first-line or after neoadjuvant chemotherapy, with analysis of histological risk factors and biomarkers at baseline and during follow-up 2024-515962-15-00 · CTIS ↗ · Eye Diseases	Phase 2	Authorised	Institut Curie	France
BASTION – Phase II Trial of BrECADD in HIV-Positive Patients with Advanced-Stage Classic Hodgkin Lymphoma 2025-521749-26-00 · Hemic and Lymphatic Diseases	Phase 2	Authorised	University Of Cologne	Germany
C6461014 - A Phase 2 Interventional Study of PF-08634404 in Combination with Chemotherapy in Participants with Previously Untreated Transformed Small Cell Lung Cancer 2025-524686-24-00 · Neoplasms	Phase 2	Ongoing	Pfizer Inc	France, Italy, Spain
C6461004 - A GLOBAL PHASE 2/3 INTERVENTIONAL STUDY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY IN PARTICIPANTS WITH EXTENSIVE-STAGE SMALL CELL LUNG CANCER 2025-523522-41-00 · CTIS ↗ · Neoplasms	Phase 3	Ongoing	Pfizer Inc	France, Italy, Germany + 1 more
TIC-TAC-SAM « Comparison of two strategies of etoposide initiation in severe sporadic hemophagocytic lymphohistiocytosis in intensive care: a randomized trial » 2024-511807-41-01 · CTIS ↗ · Pathological Conditions, Signs and Symptoms	Phase 3	Authorised	Assistance Publique Hopitaux De Paris	France
International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 - A Randomized Phase III Study Conducted by the Resistant Disease Committee of the International BFM Study Group - IntReALL BCP 2020 2023-509392-17-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 3	Ongoing	Charite Universitaetsmedizin Berlin KöR	Netherlands, Czechia, Italy + 9 more
Framework for Optimizing, Refining, and Unifying Management of HSCT in Pediatric ALL. 2025-522052-13-00 · CTIS ↗ · Hemic and Lymphatic Diseases	Phase 3	Ongoing	Ospedale Pediatrico Bambino Gesu	Germany, Denmark, Finland + 14 more

Etoposide across our data

Ireland · EU · US

The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.

Licensed in Ireland (HPRA)

5 single-substance products containing Etoposide on the HPRA medicines list.

Etoposide 20 mg/ml Concentrate for Solution for InfusionAccord Healthcare Ireland Ltd. · PA2315/201/001 · Marketed
Etoposide 20 mg/ml concentrate for solution for infusionFresenius Kabi Deutschland GmbH · PA2059/036/001 · Marketed
Etoposide-Teva 20 mg/ml Concentrate for Solution for InfusionTeva Pharma B.V. · PA0749/002/001 · Marketed
VEPESID 100 mg capsule, softCHEPLAPHARM Arzneimittel GmbH · PA2239/006/002 · Marketed
VEPESID 50 mg capsule, softCHEPLAPHARM Arzneimittel GmbH · PA2239/006/001 · Marketed

All 5 Irish products →

Supply shortages

No entry for Etoposide in the EMA, FDA or German BfArM shortage lists we track.

EU shortages US shortages German shortages

Conditions studied with Etoposide

236 conditions

Extensive-stage Small-cell Lung Cancer6 Small-cell Lung Cancer6 Small Cell Lung Cancer Extensive Stage6 Small Cell Lung Cancer6 Acute Myeloid Leukemia4 Acute Lymphoblastic Leukemia4 Small Cell Lung Cancer (SCLC)3 Extensive-stage Small Cell Lung Cancer (ES-SCLC)3Germ Cell Tumor3SCLC, Extensive Stage3 Multiple Myeloma3Retinoblastoma3

All 236 conditions

Condition (as registered)	Trials
Extensive-stage Small-cell Lung Cancer	6
Small-cell Lung Cancer	6
Small Cell Lung Cancer Extensive Stage	6
Small Cell Lung Cancer	6
Acute Myeloid Leukemia	4
Acute Lymphoblastic Leukemia	4
Small Cell Lung Cancer (SCLC)	3
Extensive-stage Small Cell Lung Cancer (ES-SCLC)	3
Germ Cell Tumor	3
SCLC, Extensive Stage	3
Multiple Myeloma	3
Retinoblastoma	3
Stage III Lung Cancer AJCC v8	3
Neuroblastoma	3
Hepatoblastoma	2
Extensive-Stage Small Cell Lung Cancer	2
Small-Cell Lung Cancer	2
SCLC,Extensive Stage	2
Extensive-stage Small Cell Lung Cancer	2
Extensive Stage Lung Small Cell Cancer	2
Ovarian Neoplasms	2
Ovarian Cancer	2
Hematopoietic Stem Cell Mobilization	2
Lymphoma	2
Lung Cancer	2
Acute Lymphoblastic Leukemia, Pediatric	2
Seminoma	2
Testicular Cancer	2
Choriocarcinoma	2
Germinoma	2
Ganglioneuroblastoma	2
Ganglioneuroblastoma, Nodular	2
Small Cell Lung Carcinoma	1
Carcinoma, Hepatocellular	1
Childhood Ependymoma	1
High-risk Large B-cell Lymphoma (LBCL)	1
Hodgkin Lymphoma	1
Lung Neoplasms	1
Carcinoma, Non-Small-Cell Lung	1
Extrapulmonary Neuroendocrine Cancer (epNEC)	1
Extensive Stage Small-cell Lung Cancer	1
Advanced Solid Tumors	1
Non-small Cell Lung Cancer	1
Extensive Stage Small Cell Lung Cancer	1
Extensive-stage Small Cell Lung Carcinoma	1
Advanced Small Cell Lung Cancer	1
Small Cell Carcinoma	1
Sclc	1
Small Cell Lung Carcinoma (SCLC)	1
Non-Small Cell Lung Cancer	1
Neuroendocrine Neoplasms	1
Large Cell Neuroendocrine Cancer (LCNEC)	1
Neuroendocrine Prostate Cancer (NEPC)	1
Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC)	1
Mature B-Cell Non-Hodgkin Lymphoma	1
Small Cell Lung Carcinoma Extensive Disease	1
Hodgkin Lymphoma, Adult	1
Childhood Extracranial Germ Cell Tumor	1
Extragonadal Embryonal Carcinoma	1
Malignant Germ Cell Tumor	1
Widespread Small Cell Lung Cancer	1
Glioblastoma	1
Limited-stage Small Cell Lung Cancer (LS-SCLC)	1
Extranodal NK T Cell Lymphoma	1
Hemophagocytic Lymphohistiocytosis (HLH)	1
Extensive-Stage Small-Cell Lung Cancer	1
Extensive Disease Small Cell Lung Cancer	1
Ovarian Germ Cell Cancer	1
Relapsed/Refractory Large B-Cell Lymphoma	1
Advanced Extrapulmonary Neuroendocrine Carcinoma	1
Myelosuppression	1
Olfactory Neuroblastoma	1
Relapsed/Refractory Diffuse Large B-Cell Lymphoma	1
SCLC, Limited Stage	1
Radiation Exposure	1
Radiotherapy Side Effect	1
Progression	1
SCLC	1
Lung Cancer, Small Cell	1
Hemophagocytic Syndrome	1
Acute Leukemia, High Risk	1
Acute Leukemia Refractory	1
Acute Leukemia, Relapsed	1
Osteosarcoma	1
Solid Cancer	1
Lung	1
Radiotherapy	1
Extensive Small Cell Lung Cancer	1
Advanced Solid Tumor Cancer	1
DLBCL	1
Untreated	1
MYC Gene Rearrangement	1
Natural Killer/T-cell Lymphoma	1
AML, Childhood	1
Neuroendocrine Carcinoma of the Bladder	1
Bladder Cancer	1
Advanced Neuroendocrine Carcinoma	1
Classical Hodgkin Lymphoma	1
Child	1
Adolescent	1
Young Adult	1
Platinum Resistant Ovarian Cancer	1
Platinum Refractory Epithelial Ovarian Cancer	1
Ovarian Cancer (OvCa)	1
Ovarian Sex Cord Stromal Tumor	1
HER2-negative Breast Cancer Brain Metastases	1
Limited Stage Small Cell Lung Cancer	1
Malignant Solid Tumors	1
Neuroendocrine Carcinomas (NEC)	1
Postoperative Incidental Small Cell Lung Cancer	1
Toripalimab Adjuvant Therapy Evaluation	1
Small Cell Lung Cancer Limited Stage	1
Large-Cell Neuroendocrine Carcinoma of the Lung	1
Extrapulmonary Neuroendocrine Carcinoma	1
Primary Plasma Cell Leukemia	1
Extramedullary Multiple Myeloma	1
Non-Hodgkin's Lymphoma	1
FLT3-mutated Acute Myeloid Leukemia	1
Mature B-cell Non-Hodgkin Lymphoma	1
ENSAT Stage I Adrenal Cortex Carcinoma	1
ENSAT Stage II Adrenal Cortex Carcinoma	1
ENSAT Stage III Adrenal Cortex Carcinoma	1
B Acute Lymphoblastic Leukemia	1
Mixed Phenotype Acute Leukemia	1
T Acute Lymphoblastic Leukemia	1
Newly Diagnosed Acute Myeloid Leukemia (AML)	1
Untreated AML	1
AML Arising From Myelodysplastic Syndrome (MDS)	1
AML Arising From Antecedent Hematologic Disorder (AHD)	1
Acute Lymphoblastic Leukaemia	1
High-Risk Neuroblastoma	1
Patient With Insufficient Response Chemoimmunotherapy	1
Hemophagocytic Lymphohistiocytosis	1
Childhood Renal Tumor	1
Wilms Tumor	1
Medulloblastoma Recurrent	1
Ependymoma Recurrent	1
ATRT Recurrent	1
Rare CNS Tumor Recurrent	1
Children	1
Retinal Neoplasm	1
Sarcoma	1
B-Cell Non-Hodgkin Lymphoma (B-NHL)	1
Advanced Hodgkin Lymphoma	1
Extensive Stage Small Cell Lung Cancer (ES-SCLC)	1
Extrapulmonary Small Cell Carcinoma	1
Merkel Cell Carcinoma	1
B-cell Non Hodgkin Lymphoma	1
Acute Myeloid Leukemia in Children	1
Quality of Life	1
De-escalation	1
Limited Stage Lung Small Cell Carcinoma	1
Stage I Lung Cancer AJCC v8	1
Stage II Lung Cancer AJCC v8	1
Recurrent B Acute Lymphoblastic Leukemia	1
Central Nervous System Nongerminomatous Germ Cell Tumor	1
Embryonal Carcinoma	1
Immature Teratoma	1
Locally Advanced Lung Non-Small Cell Carcinoma	1
Stage IIB Lung Cancer AJCC v8	1
Basal Ganglia Germinoma	1
Diabetes Insipidus	1
Pineal Region Germinoma	1
Anaplastic Kidney Wilms Tumor	1
Recurrent Kidney Wilms Tumor	1
Stage II Kidney Wilms Tumor	1
Stage III Kidney Wilms Tumor	1
B Acute Lymphoblastic Leukemia, Philadelphia Chromosome Negative	1
CNS Embryonal Tumor	1
CNS, Medulloblastoma	1
Atypical Teratoid Rhabdoid Tumor	1
Medulloblastoma, Childhood	1
Adult T-Cell Leukemia/Lymphoma	1
Anaplastic Large Cell Lymphoma, ALK-Negative	1
Anaplastic Large Cell Lymphoma, ALK-Positive	1
Angioimmunoblastic T-Cell Lymphoma	1
Metastatic Ewing Sarcoma	1
Metastatic Malignant Neoplasm in the Bone	1
Metastatic Malignant Neoplasm in the Bone Marrow	1
Metastatic Malignant Neoplasm in the Lung	1
Pancreatic Ductal Carcinoma	1
Advanced Cancer	1
Epithelial Tumor	1
Localized Resectable Neuroblastoma	1
Localized Unresectable Neuroblastoma	1
Childhood Hepatocellular Carcinoma	1
Childhood Malignant Liver Neoplasm	1
Fibrolamellar Carcinoma	1
Medulloblastoma	1
Central Nervous System Embryonal Tumors	1
Glioblastoma Multiforme	1
Down Syndrome	1
Myelodysplastic Syndrome	1
Myeloid Leukemia Associated With Down Syndrome	1
Adult T Acute Lymphoblastic Leukemia	1
Ann Arbor Stage II Adult Lymphoblastic Lymphoma	1
Ann Arbor Stage II Childhood Lymphoblastic Lymphoma	1
Ann Arbor Stage III Adult Lymphoblastic Lymphoma	1
Bilateral Retinoblastoma	1
Childhood Intraocular Retinoblastoma	1
Group D Retinoblastoma	1
Stage I Retinoblastoma	1
Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8	1
Ann Arbor Stage IIB Hodgkin Lymphoma	1
Ann Arbor Stage IIIB Hodgkin Lymphoma	1
Ann Arbor Stage IVA Hodgkin Lymphoma	1
Ann Arbor Stage IVB Hodgkin Lymphoma	1
Stage I Mixed Cell Type Kidney Wilms Tumor	1
Stage II Mixed Cell Type Kidney Wilms Tumor	1
Stage III Mixed Cell Type Kidney Wilms Tumor	1
Stage IV Mixed Cell Type Kidney Wilms Tumor	1
High Grade Glioma	1
CNS Tumor	1
Diffuse Large B-Cell Lymphoma	1
Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	1
Double-Expressor Lymphoma	1
EBV-Positive Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	1
Recurrent Lung Non-Small Cell Carcinoma	1
Stage IIIA Lung Cancer AJCC v8	1
Stage IIIB Lung Cancer AJCC v8	1
Gastric Neuroendocrine Carcinoma	1
Intestinal Neuroendocrine Carcinoma	1
Pancreatic Neuroendocrine Carcinoma	1
Hemophagocytic Lymphohistiocytoses	1
B-cell Lymphoma Recurrent	1
B-cell Lymphoma Refractory	1
CNS Metastases	1
Female	1
Acute Lymphoblastic Lymphoma	1
Classical Hodgkins Lymphoma in Children and Adolescents.	1
NSCLC (non-small Cell Lung Cancer)	1
Teratoma	1
Primary Mediastinal Large B-Cell Lymphoma	1
Recurrent Acute Myeloid Leukemia	1
Refractory Acute Myeloid Leukemia	1
Mature B-Cell Lymphoma	1

By country register

Register	Trials	Recruiting
Clinical trials in China	77	54
Clinical trials in Canada	40	19
Clinical trials in Australia	36	21
Clinical trials in Israel	36	18
Clinical trials in France	32	15
Clinical trials in Germany	31	14
Clinical trials in Spain	31	13
Clinical trials in Italy	28	14
Clinical trials in USA	27	11
Clinical trials in Mexico	26	11
Clinical trials in Netherlands	24	10
Clinical trials in South Korea	22	9
Clinical trials in Poland	21	11
Clinical trials in Japan	19	7
Clinical trials in Belgium	19	9
Clinical trials in Czechia	17	10
Clinical trials in Austria	16	9
Clinical trials in Turkey	15	6
Clinical trials in Switzerland	15	6
Clinical trials in Sweden	14	9
Clinical trials in Denmark	13	6
Clinical trials in Norway	11	6
Clinical trials in UK	10	4
Clinical trials in Brazil	10	5
Clinical trials in Taiwan	10	4
Clinical trials in Portugal	6	2
Clinical trials in Ireland	5	2
Clinical trials in Egypt	4	1
Clinical trials in Singapore	3	1
Clinical trials in India	3	3
EU register (CTIS)	7	—

A trial with sites in more than one country appears in each of those registers. CTIS does not publish a recruiting flag; its trials may also appear in the registers above.

Related compounds

Questions about Etoposide trials

How many clinical trials are testing Etoposide?

164 current trials in our China, Canada, Australia, Israel, France, Germany, Spain, Italy, USA, Mexico, Netherlands, South Korea, Poland, Japan, Belgium, Czechia, Austria, Turkey, Switzerland, Sweden, Denmark, Norway, UK, Brazil, Taiwan, Portugal, Ireland, Egypt, Singapore and India registers name Etoposide (also registered as VP16) as a drug or biological intervention, as of the registry sync on 9 November 2026. Completed and withdrawn studies are not counted.

Are Etoposide trials recruiting patients?

Yes. 92 of the 164 trials are recruiting: 54 with sites in China, 19 with sites in Canada, 21 with sites in Australia, 18 with sites in Israel, 15 with sites in France, 14 with sites in Germany, 13 with sites in Spain, 14 with sites in Italy, 11 with sites in USA, 11 with sites in Mexico, 10 with sites in Netherlands, 9 with sites in South Korea, 11 with sites in Poland, 7 with sites in Japan, 9 with sites in Belgium, 10 with sites in Czechia, 9 with sites in Austria, 6 with sites in Turkey, 6 with sites in Switzerland, 9 with sites in Sweden, 6 with sites in Denmark, 6 with sites in Norway, 4 with sites in UK, 5 with sites in Brazil, 4 with sites in Taiwan, 2 with sites in Portugal, 2 with sites in Ireland, 1 with sites in Egypt, 1 with sites in Singapore and 3 with sites in India. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Who sponsors Etoposide clinical trials?

Children's Oncology Group (12), National Cancer Institute (NCI) (12), Boehringer Ingelheim (5) and Merck Sharp & Dohme LLC (4), among 103 lead sponsors in total. The number in brackets is how many trials each organisation leads.

Are there Etoposide clinical trials in Ireland?

Yes. 5 trials in our Ireland register (ClinicalTrials.gov). Some may be the same study registered in both. See the Irish clinical trials register for sites and contacts.

Is Etoposide licensed in Ireland?

Yes. The HPRA medicines list includes 5 single-substance products containing Etoposide, for example Etoposide 20 mg/ml Concentrate for Solution for Infusion (Accord Healthcare Ireland Ltd.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.

Is there a Etoposide shortage?

Not in the lists we track: Etoposide has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.

Where does this information come from?

Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Etoposide works or whether it is effective, and it is not medical advice.

How this page is built

Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Etoposide works or whether it is effective. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page

This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Etoposide (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 9 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.